Energy Transmitting Device for Tinnitus Treatment via Bone Conduction
Summary
USPTO granted patent US12594007B2 to Circius Pharma AB for an energy transmitting device using bone conduction to treat tinnitus. The patent covers a two-unit system with a first unit producing treatment energy and a second unit securing the device against the patient's skin for bone conductivity transmission. The patent contains 21 claims and was filed on July 26, 2021.
What changed
USPTO granted patent US12594007B2 to Circius Pharma AB on April 7, 2026. The patent covers an energy transmitting device and system for monitoring and treating tinnitus via bone conduction, comprising a first unit that produces treatment energy and a second unit that secures the first unit against the patient's skin. The device transmits energy through bone conductivity for tinnitus treatment. Assignee is Circius Pharma AB with inventors including Peter Arndt, Fredrik Westman, Arash Golshenas, and Ali Jehanfard. The patent contains 21 claims.
This is a patent grant notice with no compliance obligations. Entities developing competing tinnitus treatment devices should review the patent claims to assess potential infringement risks. Medical device manufacturers and pharmaceutical companies in the hearing/healthcare sector should consider this intellectual property when designing bone conduction or tinnitus treatment products.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Energy transmitting device and system to monitor and treat tinnitus
Grant US12594007B2 Kind: B2 Apr 07, 2026
Assignee
Circius Pharma AB
Inventors
Peter Arndt, Fredrik Westman, Arash Golshenas, Ali Jehanfard
Abstract
Disclosed is an energy transmitting device for use in a system to monitor and treat tinnitus, comprising: a first unit that produces energy for treating said tinnitus; and a second unit that is arranged to secure and fasten said first unit against a skin of said patient, wherein, when in operation, said first unit produces said energy based on a suggested treatment for transmission to said patient through bone conductivity for treating said tinnitus.
CPC Classifications
A61B 5/05 A61B 5/024 A61B 5/128 A61B 5/1455 A61B 5/6815 A61F 11/045 A61H 23/02 A61M 21/00 A61M 21/0022 A61M 21/0027 A61M 21/0072 A61N 1/0492 A61N 1/36036 A61N 2/006 A61N 5/0613 A61N 5/067 A61P 27/16
Filing Date
2021-07-26
Application No.
18004834
Claims
21
Related changes
Get daily alerts for USPTO Patent Grants - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Diagnosis & Surgery (A61B) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.